GlycoMimetics (GlycoMimetics) FCF Margin % : -76,160.00% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. GlycoMimetics's Free Cash Flow for the three months ended in Dec. 2023 was $-7.62 Mil. GlycoMimetics's Revenue for the three months ended in Dec. 2023 was $0.01 Mil. Therefore, GlycoMimetics's FCF Margin % for the quarter that ended in Dec. 2023 was -76,160.00%.

As of today, GlycoMimetics's current FCF Yield % is -33.02%.

The historical rank and industry rank for GlycoMimetics's FCF Margin % or its related term are showing as below:

GLYC' s FCF Margin % Range Over the Past 10 Years
Min: -349020 Med: -4957.33 Max: -29.91
Current: -349020

During the past 13 years, the highest FCF Margin % of GlycoMimetics was -29.91%. The lowest was -349020.00%. And the median was -4957.33%.

GLYC's FCF Margin % is ranked worse than
99.03% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs GLYC: -349020.00

GlycoMimetics FCF Margin % Historical Data

The historical data trend for GlycoMimetics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoMimetics FCF Margin % Chart

GlycoMimetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-386.81

-4,957.33

-62,054.67

-349,010.00

GlycoMimetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-76,160.00

Competitive Comparison of GlycoMimetics's FCF Margin %

For the Biotechnology subindustry, GlycoMimetics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlycoMimetics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's FCF Margin % falls into.

GlycoMimetics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

GlycoMimetics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-34.901	/	0.01
	=	-349,010.00 %

GlycoMimetics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-7.616	/	0.01
	=	-76,160.00 %

GlycoMimetics FCF Margin % Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

GlycoMimetics (GlycoMimetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (NAS:GLYC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

GKO:Germany

Address

9708 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.glycomimetics.com

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.

Executives

Edwin Rock	officer: Chief Medical Officer	9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Brian M. Hahn	officer: CFO	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Daniel M Junius	director	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Bruce S Johnson	officer: SVP & Chief Commercial Officer	9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850
Chinmaya Rath	officer: SVP and Chief Business Officer	9708 MEDICAL CENTER DR., ROCKVILLE MD 20850
Invus Public Equities, L.p.	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Invus Public Equities Advisors, Llc	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Artal Group S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal International S.c.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
S.a. Westend	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Administratiekantoor Westend Stichting	10 percent owner	CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD
Artal International Management S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Amaury Wittouck	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661
Scott D Sandell	10 percent owner
Harout Semerjian	director, officer: Chief Executive Officer	300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950